Estrogen plus progestin and lung cancer | 雌激素加孕激素和肺癌

中文版谷歌中文翻譯(90% 準確率) | English translation
Buy/Sell Your Domains Here。在這裡購買/出售您的域名
Contact Dr. Lu for information about cancer treatments。聯繫盧博士,獲取有關癌症治療資訊。

Estrogen plus progestin and lung cancer

Previous studies of data from the Women’s Health Initiative study have shown that hormone replacement therapy can increase the risk of breast cancer and heart disease. New research based on the same set of data now suggests that hormone replacement therapy may also increase the risk of lung cancer death in female hormone users.

For the study, scientists at the Los Angeles Biomedical Research Institute at UCLA Medical Center in Los Angeles and other organizations analyzed data from 16,608 postmenopausal women aged 50 to 79. Subjects were randomized to receive 0.625 mg conjugated equine estrogen plus 2.5 mg medroxyprogesterone acetate or placebo. They were followed for a total of 14 years.

The study found that women who used hormones were 12 percent more likely to develop lung cancer. And these women were more likely to die from lung cancer, but the difference between the study and control groups was not significant.

The study showed that the women’s risk of death was attenuated during the 14-year follow-up period compared with the risk over a 4.5-year period of hormone therapy. Early research showed that women who received hormone therapy had a 71 percent higher risk of dying from lung cancer than those who did not receive it during the first 8 years of follow-up.

The study concluded that the risk of death from lung cancer was high but decreased over time. The chronic effect of hormone replacement therapy on the risk of death from lung cancer almost disappeared 14 years after the intervention, while the risk of developing cancer was 12% higher than in the control group.

A combination of estrogen and progestin is used in the West to relieve postmenopausal symptoms in women.

雌激素加孕激素和肺癌

以前对妇女健康倡议研究数据的研究表明,激素替代疗法可增加乳腺癌和心脏病的风险。基于同一组数据的新研究现在表明,激素替代疗法也可能增加女性激素使用者的肺癌死亡风险。

对于这项研究,洛杉矶加州大学洛杉矶分校医学中心的洛杉矶生物医学研究所的科学家和其他组织分析了数据来自16,608名50至79岁的绝经后妇女。将受试者随机分为接受0.625毫克缀合的马雌激素加2.5毫克醋酸甲羟孕酮或安慰剂。他们被跟踪了总共14年。

研究发现使用激素的妇女发生肺癌的可能性增加了12%。而且这些妇女更有可能因肺癌而死亡,但研究组与对照组之间的差异并不显着。

研究显示,与激素治疗4.5年的时间的风险相比,14年随访期间妇女的死亡的风险已经减弱。早期研究显示,在接受头8年的随访中,接受激素治疗的女性患肺癌死亡风险比没有接受治疗的患者死亡71%。

该研究得出结论,肺癌死亡风险高,但随时间而减少。干预后14年,激素替代治疗对肺癌死亡风险的慢性影响几乎消失,而发展癌症的风险比对照组高12%。

雌激素和孕激素联合用于西方,以缓解女性的绝经后症状。

$$$ If you are interested in a writer or editor position, check out here.We are hiring. $$$

114